Citadel Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $203K | Sell |
16,100
-2,100
| -12% | -$28.2K | ﹤0.01% | 11393 |
|
|
2025
Q4 | $287K | Sell |
18,200
-8,400
| -32% | -$107K | ﹤0.01% | 10244 |
|
|
2025
Q3 | $318K | Buy |
+26,600
| New | +$213K | ﹤0.01% | 10218 |
|
|
2025
Q2 | – | Sell |
-5,600
| Closed | -$30.9K | – | 13175 |
|
|
2025
Q1 | $30.9K | Sell |
5,600
-4,100
| -42% | -$25.3K | ﹤0.01% | 12790 |
|
|
2024
Q4 | $55.8K | Buy |
9,700
+4,900
| +102% | +$47K | ﹤0.01% | 12274 |
|
|
2024
Q3 | $49.7K | Sell |
4,800
-5,600
| -54% | -$73.2K | ﹤0.01% | 11923 |
|
|
2024
Q2 | $135K | Buy |
10,400
+1,000
| +11% | +$13.5K | ﹤0.01% | 10497 |
|
|
2024
Q1 | $164K | Buy |
9,400
+7,500
| +395% | +$99.2K | ﹤0.01% | 10629 |
|
|
2023
Q4 | $17.9K | Buy |
1,900
+1,100
| +138% | +$10.2K | ﹤0.01% | 12719 |
|
|
2023
Q3 | $8.94K | Sell |
800
-1,000
| -56% | -$16.1K | ﹤0.01% | 13155 |
|
|
2023
Q2 | $38.5K | Sell |
1,800
-54,300
| -97% | -$1.6M | ﹤0.01% | 12096 |
|
|
2023
Q1 | $2.27M | Sell |
56,100
-85,100
| -60% | -$4.06M | ﹤0.01% | 5126 |
|
|
2022
Q4 | $6.57M | Buy |
141,200
+30,300
| +27% | +$1.38M | ﹤0.01% | 3441 |
|
|
2022
Q3 | $5.75M | Buy |
110,900
+41,500
| +60% | +$2.42M | ﹤0.01% | 3638 |
|
|
2022
Q2 | $3.28M | Buy |
69,400
+56,500
| +438% | +$3.07M | ﹤0.01% | 4590 |
|
|
2022
Q1 | $918K | Buy |
12,900
+9,500
| +279% | +$618K | ﹤0.01% | 7914 |
|
|
2021
Q4 | $254K | Buy |
+3,400
| New | +$267K | ﹤0.01% | 11313 |
|
|
2020
Q3 | – | Sell |
-4,100
| Closed | -$206K | – | 10206 |
|
|
2020
Q2 | $206K | Sell |
4,100
-27,300
| -87% | -$1.41M | ﹤0.01% | 8486 |
|
|
2020
Q1 | $1.61M | Sell |
31,400
-900
| -3% | -$48K | ﹤0.01% | 4495 |
|
|
2019
Q4 | $2M | Buy |
32,300
+24,100
| +294% | +$1.49M | ﹤0.01% | 4426 |
|
|
2019
Q3 | $493K | Sell |
8,200
-14,800
| -64% | -$1.1M | ﹤0.01% | 6776 |
|
|
2019
Q2 | $1.94M | Buy |
23,000
+11,500
| +100% | +$1.03M | ﹤0.01% | 4559 |
|
|
2019
Q1 | $1.1M | Buy |
11,500
+400
| +4% | +$35.9K | ﹤0.01% | 5417 |
|
|
2018
Q4 | $786K | Sell |
11,100
-1,500
| -12% | -$115K | ﹤0.01% | 5681 |
|
|
2018
Q3 | $1.08M | Sell |
12,600
-4,500
| -26% | -$451K | ﹤0.01% | 5413 |
|
|
2018
Q2 | $1.98M | Buy |
17,100
+8,500
| +99% | +$848K | ﹤0.01% | 4128 |
|
|
2018
Q1 | $696K | Sell |
8,600
-700
| -8% | -$53.9K | ﹤0.01% | 5330 |
|
|
2017
Q4 | $546K | Sell |
9,300
-1,900
| -17% | -$95.1K | ﹤0.01% | 5515 |
|
|
2017
Q3 | $524K | Buy |
11,200
+2,100
| +23% | +$84.4K | ﹤0.01% | 5256 |
|
|
2017
Q2 | $327K | Buy |
+9,100
| New | +$291K | ﹤0.01% | 5766 |
|
|
2016
Q3 | – | Sell |
-16,100
| Closed | -$355K | – | 7341 |
|
|
2016
Q2 | $355K | Buy |
16,100
+100
| +0.6% | +$2.62K | ﹤0.01% | 4969 |
|
|
2016
Q1 | $470K | Buy |
+16,000
| New | +$445K | ﹤0.01% | 4496 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Citadel Advisors's ENTA Position: Q1 2026 in Review
Citadel Advisors increased its Enanta Pharmaceuticals (ENTA) stake by 182% in Q1 2026, buying an estimated $2.27M and bringing the position to 262,533 shares worth $3.32M. The position accounts for ﹤0.01% of the portfolio, ranked #5069.
Citadel Advisors first reported a position in ENTA in Q4 2013 and has held it in 40 quarters since. The position peaked at $23.9M in Q1 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Citadel Advisors held 262,533 shares of Enanta Pharmaceuticals worth $3.32M as of Q1 2026.
- Citadel Advisors bought 169,375 Enanta Pharmaceuticals shares in Q1 2026, an estimated $2.27M.
- Enanta Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5069 holding.
- Citadel Advisors first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 40 quarters since.
- Citadel Advisors's Enanta Pharmaceuticals position peaked at $23.9M in Q1 2019.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.